Cerus Co. (NASDAQ:CERS) has earned an average broker rating score of 1.40 (Strong Buy) from the five analysts that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a hold rating and four have assigned a strong buy rating to the company. Cerus’ rating score has declined by 40% in the last three months as a result of various analysts’ upgrades and downgrades.
Brokerages have set a 12 month consensus price target of $8.30 for the company and are predicting that the company will post ($0.16) EPS for the current quarter, according to Zacks. Zacks has also given Cerus an industry rank of 45 out of 265 based on the ratings given to its competitors.
CERS has been the subject of a number of recent analyst reports. BTIG Research reiterated a “buy” rating and issued a $8.00 price target on shares of Cerus in a research report on Sunday, November 1st. Cantor Fitzgerald reiterated a “buy” rating and issued a $7.00 price target on shares of Cerus in a research report on Wednesday, September 30th. Finally, Wedbush lowered Cerus from an “outperform” rating to a “neutral” rating and set a $6.50 price target for the company. in a research report on Thursday, December 17th.
Shares of Cerus (NASDAQ:CERS) opened at 6.32 on Monday. The company’s 50-day moving average is $5.80 and its 200-day moving average is $5.26. Cerus has a 52-week low of $3.82 and a 52-week high of $7.03. The firm’s market cap is $613.91 million.
Cerus (NASDAQ:CERS) last released its quarterly earnings results on Thursday, November 5th. The company reported ($0.17) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.16) by $0.01. The company earned $8.04 million during the quarter, compared to analyst estimates of $10 million. During the same period last year, the business earned ($0.15) EPS. The firm’s revenue for the quarter was down 22.4% compared to the same quarter last year. Equities research analysts forecast that Cerus will post ($0.62) earnings per share for the current fiscal year.
Cerus Corporation is a biomedical products company engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company’s INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including HIV, West Nile, SARS, hepatitis B and C; bacteria and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company has commercial rights for its INTERCEPT Blood System for three blood components: platelets, plasma and red blood cells. The INTERCEPT Blood System for platelets or platelet system and the INTERCEPT Blood System for plasma or plasma system are being marketed and sold in a number of countries, including the United States, certain countries in Europe, The Commonwealth of Independent States (NASDAQ:CERS) and the Middle East. The INTERCEPT Blood System for red blood cells is in development-stage.
For more information about research offerings from Zacks Investment Research, visit Zacks.com